EGFR and adenocarcinoma: The matched group consists of 13 cases, including patients with LUAD-like subtypes who received adenocarcinoma-targeted treatments (EGFR-TKI/ Bevacizumab plus chemotherapy), and those with Non-LUAD-like subtypes who underwent SCLC-specific therapy (Chemotherapy for SCLC) (Table S2).